Clinical Review  |   May 2020
Antithrombotic Therapy for Patients With Atrial Fibrillation and Acute Coronary Syndrome or Percutaneous Coronary Intervention
Author Notes
  • From the Department of Internal Medicine (Drs Tseng and Agrwal); the Division of Cardiovascular Diseases (Dr Shamoun); and Mayo Clinic Library Services (Ms Marks) at the Mayo Clinic in Phoenix, Arizona. 
  • Financial Disclosures: None reported. 
  • Support: None reported. 
  •  *Address correspondence to Neera Agrwal, MD, PhD, 13737 N 92nd St, Scottsdale, AZ 85260-7434. Email: agrwal.neera@mayo.edu
     
Article Information
Cardiovascular Disorders
Clinical Review   |   May 2020
Antithrombotic Therapy for Patients With Atrial Fibrillation and Acute Coronary Syndrome or Percutaneous Coronary Intervention
The Journal of the American Osteopathic Association, May 2020, Vol. 120, 345-349. doi:https://doi.org/10.7556/jaoa.2020.053
The Journal of the American Osteopathic Association, May 2020, Vol. 120, 345-349. doi:https://doi.org/10.7556/jaoa.2020.053
Abstract

1. What is the clinical question? What combination antithrombotic therapy is recommended for patients with atrial fibrillation with acute coronary syndrome or patients undergoing percutaneous coronary intervention?

2. What does the evidence say? Double therapy (DT) with clopidogrel and direct oral anticoagulants (specifically, dabigatran, rivaroxaban, and apixaban) is noninferior to warfarin-based therapies for most patients. Double therapy is noninferior to triple therapy (TT) and has less bleeding complications.

3. What is the take-home message for physicians? According to the latest guidelines by the ACC, AHA, ESC, and HRS, in patients with AF undergoing PCI, DT with DOACs (specifically dabigatran, rivaroxaban and apixaban) plus clopidogrel is acceptable. Patients undergoing PCI or with high ischemic risk may still benefit from TT for at least 1 month and up to 6 months before switching to DT. Currently, there is no specific guidance on long-term antiplatelet therapy in these patients. Duration of antiplatelet therapy, whether with DT or TT, should be based on current DAPT guidelines (depending on indication and type of intervention) and discussions with each patient's cardiologist.

Subscribe to view more

For full access to this article, log in to an existing user account, purchase an annual subscription, or purchase a short-term subscription.

Order a subscription

Subscribe

Pay Per View

Entire Journal
30-Day Access

$50.00

Buy Now

This Issue
7-Day Access

$25.00

Buy Now

This article
24-Hour Access

$10.00

Buy Now

Sign In Or Create an account

Please sign in using your Osteopathic.org login.
If you do not have an AOA login, you may create a new account.

Or Subscribe